## nature research

Corresponding author(s):	Yali Dou
Last updated by author(s):	Mar 24, 2021

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<b>~</b> .			
Sta	١Ť١	ST.	$\Gamma \cap S$

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X	A description of all covariates tested
$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

## Software and code

Policy information about <u>availability of computer code</u>

Data collection | IconNMR; NMRPipe; NMRFAM-Sparky; PRIMUS (GUI version);

Data analysis C-I-TASSER; LOMETS; FG-MD; MotionCorr2; CTFFIND4.1; cryoSPARC; PHENIX; MolProbity; Bowtie2 (v2-2.2.4); SAMtools (v1.5); deepTools3

(v3.2.1); BEDTools; MACS (v 1.4.2); GraphPad Prism 7.0; ImageJ.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

ChIP-seq dataset for DPY30 and MLL1 were downloaded from GEO GSE26136 and GEO GSE107406, respectively. Dataset for HA-ASH2L and H3K4me3 is accessible with accession code GSE146933 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146933].

Cryo-EM structures for the 5MLL1-NCP complex and the ySET1-NCP can be accessed by PDB ID: 6PWV [https://www.rcsb.org/structure/6PWV] and EMDB: EMD-20512; PDB: 6KIX [https://www.rcsb.org/structure/6KIX], EMDB: EMD-0694; and PDB: 6UGM [https://www.rcsb.org/structure/6UGM], EMDB: EMD-20765. The accession numbers for the 4-MLL1-NCP class01; class02; and class05 cryo-EM structures, reported in this study, are PDB 6W5I [https://www.rcsb.org/structure/6W5I] and EMDB EMD-21542; PDB 6W5M: [https://www.rcsb.org/structure/6W5M] and EMDB: EMD-21544, respectively.

Source data are prov	ided with this pa	per.		
Field-spe	cific re	eporting		
	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
\times Life sciences		Behavioural & social sciences Ecological, evolutionary & environmental sciences		
-or a reference copy of t	he document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Lite scier	ices stu	udy design		
All studies must dis	close on these	points even when the disclosure is negative.		
Sample size	_	We used biological duplicates for the CUT&RUN experiments and biological triplicates for the CHIP-qPCR experiments. The sample size selection was based on statistical considerations.		
Data exclusions	There is no data	a exclusion in our study.		
Replication	All experiments	s have been successfully replicated for at least three times. Reproducibility statement is included in Methods section.		
Randomization	Randomization	was not considered since all experiments were performed in vitro.		
Blinding	No blinding was	s used since all experiments were performed in vitro by one person and it is not possible to set up blinding experiments.		
	No billiating was asca since an experiments were performed in vitro by one person and reas not possible to see up billiating experiments.			
Materials & expenses and a linvolved in the Materials & expenses and a linvolved in the Materials & Eukaryotic	perimental s e study	ystems  Methods  n/a Involved in the study  ChIP-seq  Flow cytometry		
	cell lilles ogy and archaeol			
	d other organism	—ı—		
Human res	earch participant	ts		
Clinical dat				
Dual use re	esearch of concer	'n		
Antibodies				
Antibodies used				
Antibodies dised	(Millip whole	(Millipore, cat# 07-473, 1:10000), Rabbit anti-Histone H3 (Abeam, #ab1791, 1:20000), anti-Rabbit lgG Horseradish Peroxidaselinked whole antibody (GE Healthcare, #NA934, 1:10000), and anti-HA (clone C29F4) rabbit monoclonal antibody (Cell signaling technology, cat #3724, 1:1000).		
Validation	The primary antibodies against modified histone H3K4 are validated by the manufacture using modified H3 peptides and further confirmed in the lab for specificity using histone H3 with or without MLL1 mediated methylation. The primary antibody for HA is			
	validat	ted, by manufacture by immunoblot and immunofluorecence for the antigen.		
Eukaryotic c	ell lines			
Policy information				
		E14tg2a (E14) (ATCC, #CRL-1821TM)		
Authentication		Authentication was done by karyotyping		
/ 1		All cell lines are tested negative for mycolasma contamination using the Lookout® Mycoplasma PCR Detection Kit (SIGMA ALDRICH, #MP0035) according to the manufacturer's instructions		

Commonly misidentified lines (See ICLAC register)

No commonly misidentified lines were used in this study

in | reporting summary